Ausgabe 2/2020
Inhalt (32 Artikel)
The exosome secretion inhibitor neticonazole suppresses intestinal dysbacteriosis-induced tumorigenesis of colorectal cancer
Lei Gu, Yidong Xu, Wangyan Xu, Meng Li, Hui Su, Cong Li, Zhongchen Liu
Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a
Jianguo Bai, Jianfei Wu, Ruifeng Tang, Chao Sun, Junwei Ji, Zhaolin Yin, Guangjun Ma, Wei Yang
Midkine silencing enhances the anti–prostate cancer stem cell activity of the flavone apigenin: cooperation on signaling pathways regulated by ERK, p38, PTEN, PARP, and NF-κB
Suat Erdogan, Kader Turkekul, Ilker Dibirdik, Zeynep B. Doganlar, Oguzhan Doganlar, Ayhan Bilir
A preclinical evaluation of thiostrepton, a natural antibiotic, in nasopharyngeal carcinoma
Yen-Bin Hsu, Ming-Chin Lan, Yu-Lun Kuo, Chi-Ying F. Huang, Ming-Ying Lan
Anticancer activity, apoptosis and a structure–activity analysis of a series of 1,4-naphthoquinone-2,3-bis-sulfides
Kevin W. Wellington, Natasha I. Kolesnikova, Vincent Hlatshwayo, Sourav T. Saha, Mandeep Kaur, Lesetja R. Motadi
Identification of a 3,3-difluorinated tetrahydropyridinol compound as a novel antitumor agent for hepatocellular carcinoma acting via cell cycle arrest through disturbing CDK7-mediated phosphorylation of Cdc2
Wu Bi, Ji-chang Xiao, Rui-jie Liu, Liu-ying Zhou, Sai Zhang, Mei Yang, Peng-fei Zhang
Pam3CSK4, a TLR2 ligand, induces differentiation of glioblastoma stem cells and confers susceptibility to temozolomide
Javier Megías, Alba Martínez, Teresa San-Miguel, Rosario Gil-Benso, Lisandra Muñoz-Hidalgo, David Albert-Bellver, Amara Carratalá, Daniel Gozalbo, Concha López-Ginés, María Luisa Gil, Miguel Cerdá-Nicolás
Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling
Lei Zhang, Qiaoling Song, Xinxin Zhang, Li Li, Ximing Xu, Xiaohan Xu, Xiaoyu Li, Zhuoya Wang, Yuxi Lin, Xin Li, Mengyuan Li, Fan Su, Xin Wang, Peiju Qiu, Huashi Guan, Yu Tang, Wenfang Xu, Jinbo Yang, Chenyang Zhao
Expression of the PTEN/FOXO3a/PLZF signalling pathway in pancreatic cancer and its significance in tumourigenesis and progression
Qiubo Zhang, Xuanna Li, Yaqing Li, Shaojie Chen, Xiaoling Shen, Xianwen Dong, Yufei Song, Xuesong Zhang, Kaihong Huang
Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway
Gaochao Hou, Xiang Yuan, Yi Li, Gaoyu Hou, Xianli Liu
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML
Jae Yoon Jeon, Qiuhong Zhao, Daelynn R. Buelow, Mitch Phelps, Alison R. Walker, Alice S. Mims, Sumithira Vasu, Gregory Behbehani, James Blachly, William Blum, Rebecca B. Klisovic, John C. Byrd, Ramiro Garzon, Sharyn D. Baker, Bhavana Bhatnagar
Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer
Qing-Hua Liu, Hong-Mei Yong, Qing-Xin Zhuang, Xu-Ping Zhang, Ping-Fu Hou, Yan-Su Chen, Ming-Hua Zhu, Jin Bai
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
Bo Mi Ku, Yeon Hee Bae, Kyoung Young Lee, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn
Apoptosis induction and cell cycle arrest of pladienolide B in erythroleukemia cell lines
Joana Jorge, Sara Petronilho, Raquel Alves, Margarida Coucelo, Ana Cristina Gonçalves, José Manuel Nascimento Costa, Ana Bela Sarmento-Ribeiro
Anticancer activities of vitamin K3 analogues
Kevin W. Wellington, Vincent Hlatshwayo, Natasha I. Kolesnikova, Sourav Taru Saha, Mandeep Kaur, Lesetja R. Motadi
A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer
Jeanetta Stega, Marcus S. Noel, Alexander G. Vandell, Damian Stega, Giuseppe Del Priore, Steve Hoffman
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma
C. Even, U. Lassen, J. Merchan, C. Le Tourneau, J-C Soria, C. Ferte, F. Ricci, J. T. Diener, E. Yuen, C. Smith, G. J. Oakley III, K. A. Benhadji, Christophe Massard
Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer
Takako Eguchi Nakajima, Narikazu Boku, Ayako Doi, Hiroyuki Arai, Takuro Mizukami, Yoshiki Horie, Naoki Izawa, Mami Hirakawa, Takashi Ogura, Takashi Tsuda, Yu Sunakawa
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Geoffrey I. Shapiro, Patricia LoRusso, Eunice Kwak, Susan Pandya, Charles M. Rudin, Carla Kurkjian, James M. Cleary, Mary Jo Pilat, Suzanne Jones, Alex de Crespigny, Jill Fredrickson, Luna Musib, Yibing Yan, Matthew Wongchenko, Hsin-Ju Hsieh, Mary R. Gates, Iris T. Chan, Johanna Bendell
Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
Bin Fan, Ingo K. Mellinghoff, Patrick Y. Wen, Maeve A. Lowery, Lipika Goyal, William D. Tap, Shuchi S. Pandya, Erika Manyak, Liewen Jiang, Guowen Liu, Tara Nimkar, Camelia Gliser, Molly Prahl Judge, Sam Agresta, Hua Yang, David Dai
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies
Noboru Yamamoto, Baek-Yeol Ryoo, Bhumsuk Keam, Masatoshi Kudo, Chia-Chi Lin, Futoshi Kunieda, Howard A. Ball, Diarmuid Moran, Kanji Komatsu, Kentaro Takeda, Musashi Fukuda, Junji Furuse, Satoshi Morita, Toshihiko Doi
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
Emilie M. J. van Brummelen, Evgeny Levchenko, Manuel Dómine, Dean A. Fennell, Hedy L. Kindler, Santiago Viteri, Shirish Gadgeel, Pilar Garrido López, Vladimir Kostorov, Daniel Morgensztern, Sergey Orlov, Marjorie G. Zauderer, Johan F. Vansteenkiste, Katherine Baker-Neblett, James Vasquez, Xiaowei Wang, David I. Bellovin, Jan H. M. Schellens, Li Yan, Ionel Mitrica, M. Phillip DeYoung, José Trigo
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
Takahiro Ebata, Toshio Shimizu, Yutaka Fujiwara, Kenji Tamura, Shunsuke Kondo, Satoru Iwasa, Kan Yonemori, Akihiko Shimomura, Shigehisa Kitano, Takafumi Koyama, Natsuko Sato, Kiyohiko Nakai, Michiyasu Inatani, Noboru Yamamoto
A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC
Meijuan Huang, Youling Gong, Jiang Zhu, Yi Qin, Feng Peng, Li Ren, Zhenyu Ding, Yongmei Liu, Chengzhi Cai, Yongsheng Wang, You Lu
Prospective, randomized, cross-over pilot study of the effects of Rikkunshito, a Japanese traditional herbal medicine, on anorexia and plasma-acylated ghrelin levels in lung cancer patients undergoing cisplatin-based chemotherapy
Tomoharu Yoshiya, Takahiro Mimae, Masaoki Ito, Shinsuke Sasada, Yasuhiro Tsutani, Kenichi Satoh, Takeshi Masuda, Yoshihiro Miyata, Noboru Hattori, Morihito Okada
Impact of l-carnitine on imatinib-related muscle cramps in patients with gastrointestinal stromal tumor
Heejung Chae, Min-Hee Ryu, Jungeun Ma, Moyeol Beck, Yoon-Koo Kang
Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma
Jian Zhao, Junmei Lei, Junyan Yu, Chengyan Zhang, Xuefeng Song, Ninggang Zhang, Yusheng Wang, Suxiang Zhang
Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial
Jun Cao, Quchang Ouyang, Shusen Wang, Joseph Ragaz, Xiaojia Wang, Yuee Teng, Biyun Wang, Zhonghua Wang, Jian Zhang, Leiping Wang, Jiong Wu, Zhimin Shao, Xichun Hu
The structure and regulation of the E3 ubiquitin ligase HUWE1 and its biological functions in cancer
Xiaofeng Gong, Danyu Du, Yanran Deng, Yuqi Zhou, Li Sun, Shengtao Yuan
Anticancer evaluation of a novel dithiocarbamate hybrid as the tubulin polymerization inhibitor
Jia Liu, Dongwei Xue, Xingwang Zhu, Liu Yu, Minghuan Mao, Yili Liu
Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis
Masashi Ishikawa, Satoru Iwasa, Kengo Nagashima, Masahiko Aoki, Hiroshi Imazeki, Hidekazu Hirano, Hirokazu Shoji, Yoshitaka Honma, Natsuko Okita, Atsuo Takashima, Ken Kato, Masayuki Saruta, Narikazu Boku
Dirty deeds done dirt cheap: sensitization of prostate cancer cells to abiraterone treatment using hydroxylated polychlorinated biphenyls
Gabriel Daragan, Jenny Hoffmann, Theresa Vasko, Alexander Mustea, Martin Burchardt, Thomas Kraus, Matthias B. Stope, Patrick Ziegler